Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology (MIT) to a family of early-stage monoclonal antibodies that target dengue virus….
Visterra secures exclusive patent license for promising dengue virus antibodies from MIT
No comments:
Post a Comment